

Simultaneous Estimation of Luliconazole and Clobetasol Propionate by RP-HPLC

Joyson Paul, Rohit Bhatia*

Department of Pharmaceutical Analysis, ISF College of Pharmacy Moga, India

ABSTRACT

A Simple, specific, accurate, precise, rapid, robust and selective stability-indicating reverse-phase high-performance liquid chromatography (RP-HPLC) method has been developed, Validated for the simultaneous estimation for the antifungal (Luliconazole) and anti-inflammatory (Clobetasol Propionate) drugs. Forced degradation studies were done for the evaluation of the stability of the product. The mobile phase used in the method development and validation was Acetonitrile: Water: Methanol (70:15:15). The column used was Waters (Sunfire) X Bridge C18 column (250 mm×4.6 mm, 5 μm) with a flow rate of 1 mL/min. Both the drugs were simultaneously detected at 250 nm and the Retention Time was found to be 1.87 min for Luliconazole and 4.35 min for Clobetasol Propionate. The method has been linear for both drugs. The Linearity of Luliconazole was found at 8-12 μg/mL and 0.40-0.60 μg/mL for Clobetasol Propionate. The Regression Coefficient was found to be 0.9997 for Luliconazole and for Clobetasol Propionate 0.9998. The method has been robust under various Conditions with variations in flow rate, Temperature and Wavelength. The developed method can be used routinely for simultaneous estimation of drugs Luliconazole and Clobetasol Propionate.

Keywords: Luliconazole; Clobetasol propionate; Method development; Antifungal; Anti-inflammatory; Simultaneous estimation

INTRODUCTION

Luliconazole is chemically an imidazole derivative which prevents fungal infection [1-2] (Figure 1). It is useful in treating tinea corporis, tinea cruris and tinea pedis. It acts on the 14 alpha demethylase of cytochrome p450 and inhibits the production of ergosterol which is a building block of cell membrane and leads to the destruction of fungi cell membrane [3,4]. 21-chloro-9β-fluoro-11β, 17β-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17- propionate is a chemical name of Clobetasol Propionate (Figure 1). It belongs to the class of corticosteroid [5]. It is a super-potent synthetic di-halogenated analogue of prednisolone. It acts by inhibiting the precursor of arachidonic acid (COX-2 and Phospholipase A) by binding to the receptor and sending signal to decrease proinflammatory proteins, thereby decreasing inflammation [6-7]. Therefore, Clobetasol is used topically on the skin to treat swelling, itching and irritation. It is used for the prevention of Psoriasis also (skin disease that causes red, itchy scaly patches, most commonly on the knees, elbows and scalps) [8-10].





Figure 1: Chemical Structure of the drugs: (a) Clobetasol Propionate (b) Luliconazole.

The mentioned drugs have been reported either individually or in a combination of two or separately but do not involve in simultaneous estimation of Luliconazole and Clobetasol Propionate. Literature survey revealed the method for determination of Luliconazole and Clobetasol Propionate with other drug combinations like RP-HPLC [11-13], UV Spectroscopy [14-17], High-Performance Thin Layer Chromatography [18-20]. But no methods have been reported for simultaneous determination of Luliconazole and Clobetasol Propionate in the combined topical dosage form. Hence a successful attempt has been made to estimate these drugs simultaneously by RP-HPLC method in the present work. The proposed methods were optimised and validated as per ICH guidelines.

Correspondence to: Rohit Bhatia, Department of Pharmaceutical Analysis, ISF College of Pharmacy Moga, India, E-Mail: bhatiarohit5678@gmail.com

Received: August 02, 2021; **Accepted:** August 16, 2021; **Published:** August 23, 2021

Citation: Joyson P, Rohit B (2021) Simultaneous Estimation of Luliconazole and Clobetasol Propionate by RP-HPLC. J Chromatogr Sep. 12:446

Copyright: © 2021 Rohit B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

MATERIALS AND METHODS

Experimental chemicals

RP-HPLC method: The chromatographic analysis was performed on HPLC system of WATERS (Milford, USA) composed of 515 HPLC pump as a solvent delivery system equipped with Rheodyne injection valve with a 20 μ L loop, WATERS 2498 detector and separation was performed on C18 column (4.6 mm \times 150 mm, 5 μ m i.d.) at 25°C column temperature. Chromatographic data were recorded and processed using EMPOWER-2 software.

Reagents and materials

Working standard grade of Luliconazole and Clobetasol Propionate was supplied by ISF Analytical Laboratory (Punjab, India), Luviv- CT, marketed formulation with label claim 1% of Luliconazole and 0.05% Clobetasol Propionate. Acetonitrile, Methanol, Water of HPLC grade, 0.45 mm PVDF filters were also supplied by Sd-fine Ltd.

Optimization of chromatographic conditions

Selection of proper HPLC method depends upon nature of drugs (ionic or neutral molecule), its molecular weight and its solubility. RP-HPLC method was selected initial separation because of its simplicity, efficiency, reproducibility, and recommended use for ionic and moderate to non-polar compounds. To optimize the chromatographic conditions, chromatographic variables such as mobile phase, pH, flow rate, column temperature, and solvent ratio were studied. The condition that gave best resolution, symmetry, theoretical plates and capacity factor was selected for estimation.

Optimized chromatographic condition

The optimised condition after many trials has been given in Table 1.

Table 1: Optimized Chromatographic Conditions

Mobile Phase	ACN: Water: MeOH
Ratio	70:15:15 (0.1 %Formic Acid)
pH	3
Column	C18 Sunfire
Wavelength	250nm
Detector	UV Detector
Injection Volume	20uL
Diluent	Methanol
Flow Rate	1mL/min.
Run Time	10min.

Selection of wavelength

The sensitivity of HPLC method with UV detection depends on the proper selection of detection wavelength. An ideal wavelength is the one, at which both drugs gives a good response. In the present study, standard solutions of Luliconazole and Clobetasol Propionate were scanned over the range of 200-400 nm. Wavelength of Luliconazole and Clobetasol Propionate 250 nm was selected for analysis because of Clobetasol Propionate is low dose concentration in cream formulation.

Preparation of mobile phase

The mobile phase was prepared by mixing the HPLC grade Acetonitrile, Methanol, Water at ratio of (70:15:15). Maintain the pH at 3 by Formic acid. Filter it by 0.45 μ m filter membrane, Sonicate for 25 minutes.

Preparation of standard solution and test solutions

Standard Solution for Luliconazole: Weigh 10 mg of Luliconazole was transferred in 10 mL of Volumetric Flask make up the volume up to methanol (1000 μ g/mL) From the above stock pipette out 1 mL and transfer to 10 mL volumetric flask and make up the volume with Methanol (100 μ g/mL). Pipette out 1 mL from the 100 μ g/mL and transfer to 10 mL volumetric flask and make up the volume by Methanol.

Standard solution for clobetasol propionate: Weigh 10 mg of Clobetasol Propionate was transferred in 10 mL of volumetric flask make up the volume up to methanol (1000 μ g/mL) From the above stock Solution pipette out 1 mL and transfer to 10 mL volumetric flask and make up the volume with methanol (100 μ g/mL). Pipette out 1 mL from 100 μ g/mL and transfer to 10 mL volumetric flask and make up the volume by methanol (10 μ g/mL). Now pipette out 0.5 mL from 10 μ g/mL and make the volume in 10 mL volumetric flask.

Combined standard solution: 1 mL of Luliconazole Dilution was pipette out and 4 mL of Clobetasol Propionate Dilution were pipette out and mix well, filter and from this mixture 20 μ L was injected through rheodyne syringe.

Preparation of calibration curve: The calibration curve was prepared by injecting concentration of 0.40-0.60, 8-12 μ g/mL of Luliconazole and Clobetasol Propionate and tertiary mixture solutions manually in triplicate to the HPLC system at detection wavelength of 250 nm. Mean of n=5 determinations was plotted as the standard curve. The calibration curve was tested and validated with interday and intraday measurements.

RESULTS

Method validation

The proposed method's analytical validation parameters were determined according to International Conference on Harmonization (ICH) guidelines. Analysis of sample was carried out using the above method and the result are show in Table 1.

Linearity and range

Linearity of the method was established by analysis of combined standard solution. The range of an analytical procedure is the interval between the upper and lower concentrations (amounts) of analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity. Mixed standard solution of Luliconazole and Clobetasol Propionate were prepared with methanol in such a way that the five different concentrations of Luliconazole and Clobetasol Propionate in the range of 8-12 μ g/mL and 0.40-0.60 μ g/mL respectively. The peak area was recorded for all the peaks as shown in Table 2 for linearity of Luliconazole and Clobetasol Propionate Tables 3 and 4. The plots of peak area versus the respective concentration were found to be linear with regression coefficient ($r^2=0.9997$) for Luliconazole and ($r^2=0.9998$) for Clobetasol Propionate as

shown in Figure 2.




Figure 2: Chromatogram of Luliconazole and Clobetasol Propionate Accuracy.

Table 2: Assay of Luliconazole and Clobetasol Propionate.

	Label claim (mg)	Amount found (mg)	% Estimation (mg)
Luliconazole	1000 mg	992 mg	99.28
Clobetasol Propionate	50 mg	50.02 mg	100.04

Table 3: Conc. vs. Area.

Conc. ($\mu\text{g/mL}$)	Area
8	253405
9	274311
10	293780
11	315989
12	336789

Table 5: Percentage Recovery for Luliconazole.

Sr.No.	Recovery Sample			Fortified Sample			
	Conc. (%)	Peak Area	Mean Area	Conc. (%)	Peak Area	Mean Peak Area	% Recovery
1	80	253405	253419	80+100	610174	546907	99.98
		254334			610176		
2	100	293780	293782	100+100	966319	587564	100
		293814			966300		
3	120	336789	336784	120+100	1009593	630566	100.01

Table 4: Conc. vs. Area

Conc. ($\mu\text{g/mL}$)	Area
0.4	14722
0.45	16699
0.5	18885
0.55	20985
0.6	23120

For accuracy study data from nine determinations over three concentrations at 80%, 100% and 120% of expected sample concentration covering the specified range was determined and expressed as recovery values. Accuracy of the proposed method was evaluated by spiking standard stock solution containing Clobetasol Propionate and Ketoconazole into placebo equivalent to amount present in sample preparation to achieve at 80%, 100% and 120% of the target concentration. Measured recovered concentration versus added concentration for Luliconazole and Clobetasol Propionate calculated percentage recovery. percentage recovery for all components were found more than 97.0%, this indicate accuracy of the method as shown in Figure 3. Recovery results are tabulated in Tables 5 and 6.




Figure 3: Blank chromatogram.


Table 6: Percentage Recovery for Clobetasol Propionate.

Sr.No.	Recovery Sample			Fortified Sample			% Recovery
	Conc. (%)	Peak Area	Mean Area	Conc. (%)	Peak Area	Mean Peak Area	
1	80	14722	14724	80+100	182345	31424	100.2
		14727			182337		
2	100	16699	16700	100+100	201346	33400	100.6
		16702			201356		
3	120	23120	23122	120+100	257896	39488	98
		14722			182345		

DISCUSSION

Precision

Intermediate Precision: The method is validated for intermediate precision by analyses of homogenous mixture of 100% test concentration of both drugs in six replicate preparations using two different analysts in two different days. For first day, same analyst analyzing the six preparations of samples and for second day different analyst utilizing same chromatographic conditions. The results obtained showed percentage RSD below 2% which is under accepted range as shown in Figure 4. Hence method is precise as described in Tables 7 and 8.


**Figure 4:** Linear graph of Luliconazole with R2=0.9997.**Table 7:** Intermediate Precision of Luliconazole.

Conc. 10 µg/mL	Analyst -1	Conc. 10 µg/mL	Analyst-2
1	293167	1	296868
2	293267	2	292874
3	293356	3	292923
4	293489	4	293104
5	293823	5	293237
6	293451	6	293567
Mean	293425.5	Mean	293762.2
± S. D.	207.9517	± S. D.	1407.499
% R.S.D.(≤ 2)	0.07087	% R.S.D (≤ 2)	0.479129

Table 8: Intermediate Precision for Clobetasol Propionate

Conc. 0.40 µg/ml	Analyst -1	Conc. 0.40 µg/ml	Analyst-2
1	14589	1	14345
2	14644	2	14883
3	14756	3	14929
4	14878	4	14943
5	14985	5	15245
6	15181	6	15177
Mean	14838.83	Mean	14920.33
± S. D.	202.9839	± S. D.	289.9073
% R.S.D.(≤ 2)	1.367924	% R.S.D (≤ 2)	1.943035

System precision: System precision was performed by the repetitive analysis of single homogenous solution of 100% test concentration 0.40 µg/mL and 10 µg/mL of Clobetasol Propionate and Luliconazole using the same instrument conditions as shown in Figures 5 and 6

**Figure 5:** Linearity and Range Chromatogram of Luliconazole with Retention time 1.87min.




Figure 6: Linearity and Range Chromatogram of Clobetasol Propionate with retention time 4.35 min.

Method precision: The method Precision was performed by utilizing six replicate preparation of 100% test concentration of Clobetasol Propionate and Luliconazole. The percentage R.S.D of area for six repetitive chromatograms of Luliconazole and Clobetasol Propionate 100% test concentration for system precision and the area of six replicates of 100% test concentration for method precision are found <2% are shown in the Tables 9 and 10.

Table 9: Method Precision for Luliconazole

Conc. 10 µg/ml	System precision Area	Conc. 10 µg/ml	Method Precision Area
1	293080	1	292456
2	293145	2	292674
3	293297	3	292823
4	293387	4	293120
5	293467	5	293217
6	293587	6	293345
Mean	293543.8	Mean	292939.2
± S. D.	446.7909	± S. D.	314.0729
% R.S.D (≤1)	0.152206	% R.S.D (≤2)	0.107214

Table 10: Method Precision for Clobetasol Propionate

Conc. 0.50 µg/ml	System precision Area	Conc. 0.50 µg/ml	Method Precision Area
1	14522	1	14345
2	14687	2	14483
3	14724	3	14829
4	14835	4	14943
5	14945	5	15045
6	15170	6	15170
Mean	14813.83	Mean	14802.5
± S. D.	205.6821	± S. D.	295.9987
% R.S.D (≤ 1)	1.388446	% R.S.D (≤ 2)	1.999654

LIMIT OF DETECTION

For Clobetasol Propionate

The LOD was performed based on the standard deviation of the response and the slope

$$\text{LOD} = 3.3 \cdot \sigma / S$$

Where σ = the standard deviation of the response

S = the slope of the calibration curve

The LOD of the Clobetasol Propionate was found to be 0.013 µg/mL

For the Luliconazole

It was also based on the Standard Deviation of the Response and the Slope

$$\text{LOD} = 3.3 \cdot \sigma / S$$

Where σ = the standard deviation of the response

S = the slope of the calibration curve

The LOD of Luliconazole was found to be 0.269 µg/mL

Limit of Quantification

Limit of Quantification

LOQ of the Clobetasol Propionate

Likewise, the LOQ was performed based on the Standard Deviation of the response and the slope

$$\text{LOQ} = 10 \cdot \sigma / S$$

Where σ = the standard deviation of the response

S = the slope of the calibration curve

The LOQ of Clobetasol Propionate was found to be 0.018 µg/mL

LOQ of Luliconazole

Based on the Standard Deviation of the Response and the Slope

$$\text{LOQ} = 10 \cdot \sigma / S$$

Where σ = the standard deviation of the response

S = the slope of the calibration curve

The LOQ of Luliconazole was found to be 0.817 µg/mL


A measure of an effective analytical method is how well its performance stands up to less than perfect implementation. Robustness can be done by any deliberate change in the procedure such as change in flow rate, change in pH, Effect of Change in wavelength (± 2 nm) and observing, and the effect over the output of the method as shown in Figure 7. The effect of change in flow rate, change in pH of mobile phase, Effect of Change in wavelength (± 2 nm) is shown in Tables 11 and 12.

Table 11: Robustness of Luliconazole

Sr. No.	Conc. ($\mu\text{g}/\text{mL}$)	Flow (1ml/min)		pH		Effect of Change in wavelength ($\pm 2\text{nm}$)	
		0.9	1.1	3.5	4	249	255
1	10	285656	304167	285774	294567	313457	311445
2	10	285759	304167	287978	294676	314354	315568
3	10	295850	304985	299113	296456	315456	317895
Mean		289088.3	3045	290955	295233	314422.3	314969.3
S.D		4781.405	337.6	5838.329	865.9357	817.5175	2667.012
%RSD		1.653	0.110	2.00	0.293	0.260	0.846

Table 12: Robustness of Clobetasol Propionate.

Sr. No.	Conc. ($\mu\text{g}/\text{mL}$)	Flow (1ml/min)		pH		Effect of Change in wavelength ($\pm 2\text{nm}$)	
		0.9	1.1	3.5	4	249	255
1	0.40	14722	25820	15234	12134	15135	15345
2	0.40	14740	25837	15578	12157	15142	15350
3	0.40	14786	25846	14856	12123	15150	15360
Mean		14749	25834	15556	12138	15142	15351
S.D		26.948	10.789	254.4	14.16	6.128	6.23
%RSD		0.182	0.041	1.63	0.116	0.040	0.040

Figure 7: Linear Graph of Clobetasol Propionate with $R^2=0.9998$

CONCLUSION

Based on the results, this study is a typical example of the development of an assay method following ICH guidelines. A new isocratic RP-HPLC method has been developed and validated for determination of Luliconazole and Clobetasol Propionate in the pharmaceutical topical formulation. The results of the validation

studies showed that the RP-HPLC method possesses significant linearity, precision, accuracy, specificity, sensitivity, high efficiency and resolution, and no interference from the excipients, as were demonstrated. The proposed method was successfully applied and is suggested for the quantitative analysis of Luliconazole and Clobetasol Propionate in combined pharmaceutical topical formulations for QC, where economy and time are essential and to assure therapeutic efficacy.

REFERENCES

1. European Pharmacopoeia, 6th ed; Council of Europe: Strasbourg, France, 2007; Volume 2, pp. 2216–2217.
2. Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H. In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. *Antimicrobial agents and chemotherapy*. 1998;42(4):967-970.
3. Marriot MS. Inhibition of sterol biosynthesis in *Candida*

- albicans by imidazole-containing antifungals. *J Gen Microbiol.* 1980; 117: 253–255.
4. Borgers M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. *Rev Infect Dis.* 1980; 22(2): 520–524.
 5. Gil C, Perez-Diaz R, Nombela C. Inhibitory and morphological effects of several antifungal agents on three types of *Candida albicans* morphological mutants. *J Med Vet Mycol.* 1994; 32: 151–162.
 6. British Pharmacopoeia, International edition, Vol. I & II, HMSO, London, 2009; 1271: 1445.
 7. British Pharmacopoeia, British Pharmacopoeia Commission, 4th ed., United Kingdom, London, 2003.
 8. Tripathi KD, *Essentials of Medical Pharmacology*, 2013.
 9. Elise A, Olsen MD, Roger C, Cornell MD. Topical clobetasol-17-propionate: Review of its clinical efficacy and safety. *J Amer Acad Dermatol.* 1986; 15(2): 246-255.
 10. Stanislaw D, Edmund G, Edyta S, Agnieszka M. Pharmaceutical availability of clobetasol- 17- propionate from cream and ointment. *Acta Poloniae Pharmaceutica-Drug Research*, 2001; 58(6): 435-438.
 11. The United States Pharmacopoeia, National Formulary. Asian edition. Rockville, MD USP Convention CD ROM Version, 476-478
 12. International Conference on Harmonization, Harmonized Tripartite Guideline, Validation of Analytical Procedures Text and Methodology, ICH Q2(R1), 2005.
 13. Gunasekar Manoharan. Development and validation of a stability-indicating rp-hplc method for the estimation of clobetasol propionate in bulk and ointment dosage form; *ejpmr*, 2017; 4(05): 119-212
 14. Mehul A, Jakasaniya, Jignesh S. Shah and Dilip G. Maheswari Simultaneous estimation of clobetasol propionate and fusidic acid in cream dosage form by reversed phase high performance liquid chromatographic method. *Pharmacophore* 2014; 5 (2): 231-238.
 15. N Amrutiya, M Madan, A Bajaj. Development and Validation of RP_HPLC Method for Simultaneous Estimation of Prednicarbate, Mupirocin and Ketoconazole in Topical Dosage Forms. *J Anal Chem.* 2010; 65(11) 1148– 1154.
 16. Bhagyashree MP, Hasumati AR, Vineet CJ, Vishnu S, Mihir B. UV spectrophotometric absorption correction method for the simultaneous estimation of clobetasol propionate and salicylic acid in its pharmaceutical dosage forms. *Pharm Analysis & Quality Assurance/1451/14.*
 17. Basavaiah K, Vamsi KP, Chandrashekar U. Validated stability-indicating ultra violet spectro photometric assay of ketoconazole in pharmaceuticals, *Int J Res Pharm Nano Sci.* 2015; 4(6): 398 - 408.
 18. Mona M. Abd-El M, Hanan M. Elwy Determination of ketoconazole and trimetazidine hydrochloride through ion-pair formation with tetraiodobismuthate, *Scholars Research Library. Der Pharma Chemica.* 2015; 7(10): 6-12
 19. Olga P, Zoran K, Vesna R. Development and validation of uv spectroscopic method for determination of ketoconazole in pharmaceutical formulations. *Int J Pharm.* 2014; 4(4): 95-101.
 20. Mrinalini C. Damle, Anuradha R. Polawar, Stability Indicating Hptlc Method for the Estimation of Clobetasol Propionate in Presence of Alkali Induced Degradation Product. *Intl J PharmTech Res* 2014; 6(6): 1914-1925.
 21. Priyanka SM, Hasumati AR, Vinit CJ. Development and validation of analytical method for Simultaneous estimation of miconazole nitrate and clobetasol Propionate in cream by hptlc method. *Pharm Sci Monit* 2014; 5(2): 255-258.